



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/174

February 12, 2026

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol – BIOCON

Subject: Press Release on financial results for the quarter and nine months ended December 31, 2025

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled **“Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr Q3FY26 EBITDA at Rs 951 Cr Q3FY26 Net Profit at Rs 144 Cr”** pertaining to the un-audited consolidated financial results of Biocon Limited for the quarter and nine months ended December 31, 2025.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance officer
ICSI Membership Number: A16328

Enclosed: Press Release and Fact Sheet

Press Release

Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr
Q3FY26 EBITDA at Rs 951 Cr
Q3FY26 Net Profit at Rs 144 Cr

Bengaluru, Karnataka, India: February 12, 2026:

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal third quarter ended December 31, 2025.

Q3FY26 | Financial Highlights

Rs 4,290 Crore
CONSOLIDATED
REVENUE

Up 11%

Rs 4,173 Crore
OPERATING REVENUE
Up 9%

Rs 951 Crore
EBITDA

Up 21%

22%
EBITDA MARGIN

Rs 226 Crore
PBT
(before exceptional item)
Up 64%

Rs 1,221 Crore
CORE EBITDA

Up 21%

29%
CORE EBITDA MARGIN

Rs 249 Crore
NET R&D INVESTMENT
8% of Revenue
(ex-Syngene)

Q3FY26 | Business Segments Revenue


Rs 2,497 Crore, Up 9% YoY
BIOSIMILARS: Biocon Biologics

Rs 851 Crore, Up 24% YoY
GENERICS: APIs & Generic Formulations

Rs 917 Crore, Down 3% YoY
CRDMO[&]: Syngene

[&] Our Research Services Business segment has been renamed as CRDMO, representing Syngene's business

SEGMENTAL REVENUE CONTRIBUTION Q3FY26



Note: Revenue contribution as a % of Revenue from Operations

Leadership Comments

BIOCON GROUP

“This quarter marks the culmination of several strategic steps that have created a stronger and simpler group structure for Biocon Limited. The ~USD 1 billion raised cumulatively through two QIPs within a span of eight months demonstrates robust and sustained investor confidence in our overall business growth and direction. The settlement of structured debt obligations earlier this year significantly strengthened our balance sheet, with an improvement in the consolidated debt-to-EBITDA ratio. This will improve PBT margins going forward with the full impact of reduced interest costs of ~INR 300 crore annually expected to be reflected in FY27. These factors are reflected in S&P’s upgrade of our Biosimilars business to BB+ with a ‘Stable’ outlook and Fitch revising its outlook to ‘Positive’. Finally, the integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited will bring to life our unified One Biocon vision.”

– Kiran Mazumdar-Shaw, Chairperson, Biocon Group

BIOCON GENERICS

“The Generics business continued to see momentum in the third quarter, delivering strong sequential and year-on-year revenue growth of 10% and 24%, respectively. This performance was driven by the ongoing launches of gLiraglutide across EU markets, alongside an improved performance in our generic formulations portfolio, supported by select new product launches and base business growth in the U.S.

Looking ahead, we will focus on expanding gLiraglutide launches to additional approved EU markets, and to the U.S. pending regulatory approval.”

– Siddharth Mittal, CEO & Managing Director, Biocon Limited

BIOCON BIOLOGICS

“Biocon Biologics reported a robust Q3FY26 performance, with EBITDA of ₹700 crore, up over 44% year on year, driven by strong demand and favorable pricing across key markets. North America continued to power growth during the quarter.

We expanded our commercial portfolio with launches of Yesintek (bUstekinumab), Kirsty (bAspart), Jobevne (bBevacizumab), and Yesafili (bAflibercept), and are preparing for the launch of Vevzuo and Bosaya our two bDenosumab products in several markets globally. Inclusion of bTrastuzumab SubQ, bNivolumab, and bPembrolizumab in addition to bPertuzumab, will further strengthen our leadership in oncology and positions us well for sustained growth.”

- Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited

SYNGENE

“The key variable impacting our third quarter performance has been the ongoing impact related to a single product from one of our large molecule biologics clients. Outside of this factor, our underlying business performance has shown steady progress, with the Research Services business continuing to secure new customers and contracts. The highlight of the quarter was the extension of our relationship with Bristol Myers Squibb through to 2035, providing both partners with a strategic ten-year horizon to further develop and expand this unique, long-standing collaboration.”

- Peter Bains, CEO & Managing Director, Syngene International Limited.

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q3FY26

In Rs Crore

Particulars	Q3FY26	Q3FY25	YoY (%)
INCOME			
Biosimilars	2,497	2,289	9
Generics	851	686	24
CRDMO/ Research Services	917	944	(3)
Inter-segment	(92)	(98)	
Revenue from operations[#]	4,173	3,821	9
Other income	117	35	237
Total Revenue	4,290	3,856	11
Net R&D Expenses	249	199	25
EBITDA	951	787	21
EBITDA Margins	22%	20%	
Core EBITDA[§]	1,221	1,007	21
Core EBITDA Margins	29%	26%	
PBT (before Exceptional Items[^])	226	138	64
Net Profit (before Exceptional Items)	124	13	844
Net Profit (Reported)	144	25	475

Figures above are rounded off to the nearest Crore; % based on absolute numbers.

Notes to financials above:

[#]Revenue from operations includes licensing income

[§]Core EBITDA is EBITDA net of R&D expense, licensing, forex, and mark-to-market movement on investments.

[^]Exceptional items: Q3 FY26: BBL share swap cost, change in labor code, inventory provisioning partially offset by the derivative gain recognized on settlement; Q3FY25: BBL working capital gain and Inventory repurpose offset by acquisition loan closure

Financial Commentary: Q3FY26

Operating Revenue for Q3FY26 grew **9%** year-on-year (YoY) to **Rs 4,173 crore**.

Core EBITDA at **Rs 1,221 crore**, grew **21%** with **core operating margins** of **29%**.

Net R&D investments for the quarter were **Rs 249 crore**, representing 8% of revenue ex-Syngene.

EBITDA for the quarter at **Rs 951 crore**, grew by **21%** with an **EBITDA margin** of **22%**.

Profit Before Tax before exceptional items is **Rs 226 crore**, an increase of **64%**.

Reported Net Profit for the quarter is **Rs 144 crore**, up **475%**.

Corporate Highlights

Biocon Limited has executed a strategic corporate action to fully integrate Biocon Biologics Limited as a wholly owned subsidiary by acquiring the stakes held by minority shareholders. The transaction valued Biocon Biologics at approximately USD 5.5 billion. This marks a pivotal step in combining the businesses to leverage our global commercial infrastructure, simplifying the corporate structure and strengthening our global position to lead in diabetes, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, generics and peptides (GLP-1s).

In January 2026, Biocon raised Rs 4,150 crore (~USD 460 million) through a successful Qualified Institutions Placement (QIP) and used the proceeds primarily to fund the cash consideration payable to Mylan (Viatris) for buying out its shareholding in Biocon Biologics. The QIP, which saw healthy interest from a diverse set of domestic and global investors, was Biocon's second equity issuance within eight months. Cumulatively, the Company raised nearly USD 1 billion.

In January, S&P Global Ratings upgraded Biocon Biologics' long-term issuer credit rating from BB to BB+, with a 'Stable' outlook. In February, Fitch Ratings revised the outlook on Biocon Biologics' Long-Term Foreign-Currency Issuer Default Rating (IDR) from 'Stable' to 'Positive'. These upgrades serve as strong external validation of the progress Biocon has made in strengthening the balance sheet.

Awards and Recognitions

- Kiran Mazumdar-Shaw honored with the prestigious **USC Business Management Award**, at the inaugural University of Southern California (USC) India Awards.
- Shreehas Tambe, CEO & Managing Director, Biocon Biologics, conferred the **ET Edge India's Impactful CEO Award** in the 'Impactful Unicorn CEO' category.
- Shreehas Tambe won the **BW Pharma World Pharma Leadership Award 2026** in the 'Visionary Leadership in Pharma' category.

Sustainability / ESG

- Biocon Limited scored 73 in the 2025 S&P Global Corporate Sustainability Assessment reflecting an improvement of 5 points over the last year.
- Biocon Biologics significantly improved its ESG score to **64** in the 2025 S&P Global Corporate Sustainability Assessment (CSA), up from **53** the previous year.
- Syngene earned its second TIME-Statista honor in six months, featuring in the 2026 'World's Best Companies in Sustainable Growth' list as a global Top 3 and India's No. 1 in the Pharma and Biotech category.

Business Highlights

BIOSIMILARS: Biocon Biologics

- **Q3FY26 Revenue from Operations at Rs 2,497 crore, up 9% YoY**
- **9MFY26 Revenue from Operations at Rs 7,676 crore, up 17% YoY**
- **Q3FY26 EBITDA is Rs 700 crore; representing EBITDA Margin of 28%**
- **Q3FY26 R&D Investments accounting for 7% of Revenue**
- **Served 6.3+ Million Patients (MAT December 2025 basis)^{##}**

^{##}12-month moving annual patient population (January 2024 to December 2025)

Business Performance

Biosimilars revenue from operations for Q3FY26 grew 9% year-on-year (YoY) to Rs 2,497 crore. EBITDA increased 44% YoY to Rs 700 crore, representing an EBITDA margin of 28%, driven by an improved product and geographic mix as well as operating leverage benefits, as the company continued to realize the benefits of economies of scale.

During the quarter, Biocon Biologics took strategic actions to deepen its portfolio, accelerate market access, and enhance commercial flexibility, supporting long-term growth.

The Company disclosed three new biosimilars assets in its pipeline – Trastuzumab subcutaneous (SC), Nivolumab and Pembrolizumab. These are among the largest oncology biologics scheduled to lose exclusivity over the next five years.

The Company gained global market entry for biosimilar Aflibercept and biosimilar Denosumab through patent settlement agreements. It also secured full and exclusive global rights for biosimilar Adalimumab from Fujifilm Kyowa Kirin Biologics (FKB), assuming end-to-end responsibility for manufacturing and commercialization along with rights for any additional development activities.

Civica launched Insulin Glargine under the CalRx brand in California in January, through its exclusive distributorship arrangement with Biocon Biologics, expanding access to an affordable, high-quality long-acting insulin analog for diabetes patients.

GENERICS: APIs & Generic Formulations

- **Q3FY26 Revenue from Operations at Rs 851 Crore, up 24% YoY**
- **9MFY26 Revenue from Operations at Rs 2,321 Crore, up 18% YoY**
- **Q3FY26 R&D Investment at Rs 76 crore, representing 9% of Revenue**

Business Performance

During the quarter, the Company launched Liraglutide for diabetes (gVictoza®) and obesity (gSaxenda®) in the Netherlands as its first ‘direct-to-market’ GLP-1 in the EU.

In the U.S., final approval was obtained for Tofacitinib Extended-Release Tablets in 11mg strength, and tentative approval for 22mg strength. Approval was also received for Everolimus tablets for oral suspension in 2mg, 3mg and 5mg strengths.

Regulatory Inspections

The Company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) from the U.S. FDA for the OSD facility in Cranbury, U.S., following an inspection conducted in October 2025.

The Company’s API plant in Visakhapatnam (Site 6) received an EIR with a VAI from the U.S. FDA following a GMP inspection conducted in November 2025.

CRDMO: Syngene

- **Q3FY26 Revenue from Operations at Rs 917 Crore, down 3% YoY**
- **9MFY26 Revenue from Operations at Rs 2,702 Crore, up 3% YoY**

Business Performance

Syngene extended its strategic research collaboration with Bristol Myers Squibb until 2035 and broadened the scope of integrated services provided to its long-term partner. The Company also strengthened its oral solid dosage platform with the commissioning of a commercial-scale facility for liquid-filled hard gelatin capsules. It expanded its advanced chemistry capabilities at its Hyderabad site to support quicker delivery of high-quality drug substances for its clients.

Note: Biocon in Q1FY26 renamed its Research Services business segment as CRDMO to represent Syngene's business model of a CRO + CMO.

Enclosed: Fact Sheet – with Financials as per IND-AS

About Biocon Limited

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the U.S., Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com Follow-us on X (formerly Twitter) @bioconlimited and **LinkedIn**: @BioconLimited for company updates. For FY25 Integrated Annual Report of Biocon [click here](#)

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its 'lab to market' capabilities to serve over 6.3 million patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients' needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20+ biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). **Website**: www.bioconbiologics.com; **Follow us on X (formerly Twitter)**: @BioconBiologics and **LinkedIn**: [Biocon Biologics](#) for company updates.

About Syngene International Ltd.

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 5,600 scientists brings both deep expertise and the capacity to deliver scientific excellence, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.5+ mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with around 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis, and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company's latest Environmental, Social, and Governance (ESG) report, visit [Syngene ESG Report](#).

FOR MORE INFORMATION	
Media	Investors
Biosimilars Business: Biocon Biologics Rumman Ahmed Senior Director – Biocon Biologics +91 98451 04173 rumman.ahmed@biocon.com	Prashant Nair Head – Investor Relations, Biocon Biologics +91 98200 95476 Prashant.nair@biocon.com
Biocon Generics business Calvin Printer Head - Corporate Communications +91 70329 69537 calvin.printer@biocon.com	

Earnings Call

The management of the Company will host an Earnings Call on **13th February, 2026 at 9:00 AM IST**, over a webcast, where the senior management will discuss the Company's performance and answer questions from participants. Details of the webcast are given below as well as on the Company website www.biocon.com under Investors >> Financial Calendar >> Earnings Call for the period ended December 31, 2025. Transcript of the conference call will be uploaded on the Company website in due course.

Zoom Webinar Details	
Date	13th February, 2026
Time	9:00 AM IST
Join Zoom Webinar	Click here to register to the earnings call

Forward-Looking Statements: Biocon

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

BIOCON GROUP

FACT SHEET

December - 2025

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q3 FY 26	Q3 FY 25	Variance %
<u>INCOME</u>			
Generics	851	686	24%
Biosimilars	2,497	2,289	9%
CRDMO*	917	944	-3%
Inter-segment	(92)	(98)	-6%
Revenue from operations #	4,173	3,821	9%
Other income	117	35	237%
TOTAL REVENUE	4,290	3,856	11%
<u>EXPENDITURE</u>			
Material & Power costs	1,441	1,454	-1%
Staff costs	821	731	12%
Research & Development expenses**	249	199	25%
Other expenses	828	686	21%
Manufacturing, staff & other expenses	3,340	3,070	9%
EBITDA	951	787	21%
Interest & Finance charges	210	223	-6%
Depreciation & Amortisation	515	425	21%
PBT	226	138	64%
Exceptional item	(293)	18	
PBT	(68)	156	-144%
Taxes	51	72	-30%
Taxes on exceptional item	(67)	3	
NET PROFIT BEFORE MINORITY INTEREST	(52)	81	-164%
Minority interest	51	53	-3%
Minority interest on exceptional item	(247)	3	
NET PROFIT FOR THE PERIOD	144	25	475%
EPS Rs.	1.1	0.2	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	124	13	844%
Exceptional item, net of taxes	20	12	
NET PROFIT FOR THE PERIOD	144	25	475%
<i># Licensing Income</i>	24	7	
<i>* Earlier 'Research Services'</i>			
<i>** Gross Research & Development expenses</i>	249	199	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q3 FY 26	Q2 FY 26	Variance %
<u>INCOME</u>			
Generics	851	774	10%
Biosimilars	2,497	2,721	-8%
CRDMO*	917	911	1%
Inter-segment	(92)	(110)	-16%
Revenue from operations #	4,173	4,296	-3%
Other income	117	93	26%
TOTAL REVENUE	4,290	4,389	-2%
<u>EXPENDITURE</u>			
Material & Power costs	1,441	1,649	-13%
Staff costs	821	838	-2%
Research & Development expenses**	249	251	0%
Other expenses	828	723	15%
Manufacturing, staff & other expenses	3,340	3,460	-3%
EBITDA	951	928	2%
Interest & Finance charges	210	272	-23%
Depreciation & Amortisation	515	473	9%
PBT BEFORE EXCEPTIONAL ITEM	226	183	23%
Exceptional item, Net	(293)	(12)	
PBT	(68)	171	-140%
Taxes	51	42	22%
Taxes on exceptional item	(67)	(3)	
NET PROFIT BEFORE MINORITY INTEREST	(52)	133	-139%
Minority interest	51	50	3%
Minority interest on exceptional item	(247)	(2)	-
NET PROFIT FOR THE PERIOD	144	85	70%
EPS Rs.	1.1	0.7	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	124	92	35%
Exceptional item	20	(7)	
NET PROFIT FOR THE PERIOD	144	85	70%
# Licensing Income	24	4	
* Earlier 'Research Services'			
** Gross Research & Development expenses	249	251	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	9M FY 26	9M FY 25	Variance %
<u>INCOME</u>			
Generics	2,321	1,970	18%
Biosimilars	7,676	6,554	17%
CRDMO*	2,702	2,624	3%
Inter-segment	(289)	(304)	-5%
Revenue from operations #	12,410	10,845	14%
Other income	290	1,171	-75%
TOTAL REVENUE	12,700	12,016	6%
<u>EXPENDITURE</u>			
Material & Power costs	4,604	4,009	15%
Staff costs	2,442	2,180	12%
Research & Development expenses**	705	627	12%
Other expenses	2,226	1,941	15%
Manufacturing, staff & other expenses	9,976	8,757	14%
EBITDA	2,725	3,260	-16%
Interest & Finance charges	759	685	11%
Depreciation & Amortisation	1,443	1,251	15%
PBT BEFORE EXCEPTIONAL ITEM	523	1,324	-61%
Exceptional item, Net	(323)	76	-
PBT	200	1,400	-86%
Taxes	104	392	-73%
Taxes on exceptional item	(74)	18	-
Deferred tax charge on withdrawal of indexation benefit	-	20	-
NET PROFIT BEFORE MINORITY INTEREST	170	970	-82%
Minority interest	162	284	-43%
Minority interest on exceptional item	(252)	17	-
NET PROFIT FOR THE PERIOD	260	669	-61%
EPS Rs.	2.0	5.6	
RECONCILIATION OF NET PROFIT FOR THE PERIOD			
NET PROFIT BEFORE EXCEPTIONAL ITEM	257	648	-60%
Exceptional item, net of taxes	3	21	
NET PROFIT FOR THE PERIOD	260	669	-61%
<i># Licensing Income</i>	31	26	
<i>* Earlier 'Research Services'</i>			
<i>** Gross Research & Development expenses</i>	705	627	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	Dec 31, 2025	Mar 31, 2025
ASSETS		
Non-current assets		
(a) Property, plant and equipment	8,906	8,708
(b) Capital work-in-progress	4,847	4,102
(c) Right-of-use assets	606	604
(d) Goodwill	17,664	16,786
(e) Other intangible assets	7,191	5,865
(f) Intangible assets under development	3,029	4,407
(g) Financial assets		
Investments	895	680
Derivative assets	97	187
Other financial assets	118	68
(i) Income tax asset, net	440	371
(j) Deferred tax asset, net	339	258
(k) Other non-current assets	317	475
Non-current assets	44,449	42,511
Current assets		
(a) Inventories	5,886	4,931
(b) Financial assets		
Investments	2,851	447
Trade receivables	6,123	5,488
Cash and cash equivalents	2,329	3,227
Other bank balances	378	893
Derivative assets	25	96
Other financial assets	486	456
(c) Other current assets	1,027	748
Current assets	19,105	16,286
TOTAL - ASSETS	63,554	58,797
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	669	600
(b) Other equity	26,582	21,044
Equity attributable to owners of the Company	27,251	21,644
Non-controlling interests	6,763	6,068
Total Equity	34,014	27,712
Non-current liabilities		
(a) Financial liabilities		
Borrowings	10,455	12,405
Lease liabilities	551	539
Derivative liabilities	56	23
Other financial liabilities	535	2,828
(b) Other non-current liabilities	478	337
(c) Provisions	370	261
(d) Deferred tax liability, net	222	358
Non-current liabilities	12,667	16,751
Current liabilities		
(a) Financial liabilities		
Borrowings	6,502	5,350
Lease liabilities	80	67
Trade payables	6,611	6,549
Derivative liabilities	226	46
Other financial liabilities	2,229	933
(b) Other current liabilities	707	1,024
(c) Provisions	298	192
(d) Income tax liability, net	220	173
Current liabilities	16,873	14,334
TOTAL - EQUITY AND LIABILITIES	63,554	58,797